# Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.

> **NCT04780438** · EARLY_PHASE1 · UNKNOWN · sponsor: **G.Gennimatas General Hospital** · enrollment: 350 (estimated)

## Conditions studied

- Atrial Fibrillation Recurrent
- Pulmonary Venous Isolation
- Catheter Ablation
- Sodium-glucose Co-transporter 2 Inhibitors

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04780438
- **Lead sponsor:** G.Gennimatas General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-01
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2021-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04780438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04780438, "Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04780438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*